Key Highlights

  • RxSight (NASDAQ:RXST) recently rose 1.7 percent to USD 4.76 even as Jefferies lowered its price target to USD 5.75 per share, part of a broader run of target cuts from multiple analysts over the past year.
  • The stock remains down 54.1 percent year to date and 27.2 percent over the past month, with a 52-week range of USD 4.48 to USD 13.22 placing the latest quote near the lower end of that span.
  • Trailing twelve month Revenue fell 13.2 percent year over year to USD 127.58 million, while gross Margin of 77.5 percent sits alongside a negative 43.2 percent Operating Margin and a negative 36.8 percent net margin.
  • The 14-day RSI stood at 33.2 with the stock below its 20-day, 50-day and 200-day moving averages of USD 5.26, USD 5.98 and USD 6.93, while short interest equaled 10 percent of shares outstanding as of September 15, 2026.

Jefferies Target Cut Extends a Year of Downgrades

Jefferies lowered its RxSight (NASDAQ:RXST) price target to USD 5.75 per share, continuing a pattern seen across much of 2026 as multiple firms, including UBS, Stifel, Bank of America and Wells Fargo, have repeatedly trimmed their targets following a stretch of sales that missed expectations and guidance cuts. The company's full-year 2026 revenue guidance of USD 120 million to USD 135 million came in below prior estimates earlier in the year, with analysts citing an elongated capital-equipment selling cycle, slower new customer ramp and flattening utilization among existing customers. RxSight has since pursued a commercial pivot intended to improve utilization and growth, though the pace of any recovery remains uncertain. The aggregated analyst view remains Buy, with a score of 2.05 on a scale where 1.0 represents Strong Buy, even as individual firms have grown more cautious.

Recent Gain Sits Against a Steep Longer-Term Decline

RxSight recently traded at USD 4.76, up 1.7 percent, within a session range of USD 4.62 to USD 4.80 and roughly in the middle of that band. The USD 0.23 advance amounted to about 0.8 times the 14-day average true range of USD 0.28, a move smaller than the stock's typical daily range. Trading Volume was about USD 2.30 million, compared with a typical full-session volume of USD 3.79 million, indicating lighter turnover accompanied the gain. The broader performance remains markedly weaker, with shares down 54.1 percent year to date and 27.2 percent over the past month, while the 52-week range of USD 4.48 to USD 13.22 places the recent quote near the lower end of that span rather than signaling a Reversal of the longer decline.

Revenue Decline Meets Negative Margins

RxSight's market Capitalization is about USD 198 million, with trailing twelve month revenue of USD 127.58 million, down 13.2 percent year over year. Gross margin of 77.5 percent contrasts sharply with an operating margin of negative 43.2 percent and a net margin of negative 36.8 percent, showing that a high gross margin has not translated into positive operating results. Return on Equity stood at negative 17.3 percent, while debt-to-equity remained low at 0.04 and cash and equivalents totaled USD 13.35 million. Short interest in RxSight (NASDAQ:RXST) equaled 10 percent of shares outstanding as of September 15, 2026, with 5.5 days of average volume required to cover those positions, adding a further consideration for investors assessing near-term trading dynamics.

Where Things Stand

Jefferies did lower its RxSight price target to USD 5.75, extending a year-long pattern of downgrades across multiple firms tied to a slower Capital equipment sales cycle and reduced guidance. The stock's modest premarket gain has not reversed a steep year-to-date decline, and negative operating and net margins remain a material counterpoint to any single-session move higher. The balance of evidence favors continued caution until utilization trends and the company's commercial pivot show measurable improvement. The next checkpoint is RxSight's subsequent quarterly results.